Bringing Precision Medicine to Cholangiocarcinoma With Mitesh J. Borad, MD is organized by i3 Health. Release Date: October 21, 2020 Expiration Date: October 20, 2021 Accreditation: Physicians i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.  MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Statement of Need: With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and Biliary Cancer Research Program at the Mayo Clinic Cancer Center in Phoenix, Arizona, joins i3 Health for a discussion that covers the efficacy and adverse events of FGFR inhibitor therapy, ongoing research related to additional therapeutic targets, and the increasing role of precision medicine in the treatment of patients with cholangiocarcinoma. Learning Objectives: Upon completion of this activity, participants should be able to: • Account for tumor genomic factors when determining treatment for patients with cholangiocarcinoma • Identify and manage toxicities from FGFR inhibitor therapy in patients with cholangiocarcinoma Faculty: Mitesh J. Borad, MD  Associate Professor of Medicine Mayo Clinic College of Medicine

Mayo Clinic Talks Podcast: Opioid Edition is organized by Mayo Clinic School of Continuous Professional Development (MCSCPD). Course opens: 01/04/2018 Course expires: 12/31/2020 Accreditation: Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Activity Description This is a three-hour long podcast series - (10) episodes - that are interviews recorded for self-paced listening. Mayo Clinic physicians discuss the new opioid prescribing guidelines and share real-life examples from their practice. The topics include assessing the patient’s candidacy for opioid therapy, and when deemed appropriate, what drug, duration and dose is recommended. Addiction and opioid use disorder are also discussed. Learning Objectives: Upon completion of this program, learners should be able to: • Identify when it is appropriate to initiate or continue opioid therapy for a patient. • Select the best opioid medication, dosage, and duration for a patient identified as a good candidate for opioid therapy. • Recognize the risks of opioid therapy and recommend treatment options for opioid use disorder. • Recall non-pharmacological and implantable device alternatives for the treatment of pain and ongoing pain management.

Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO is organized by i3 Health. Release: August 20, 2020 Expiration: August 19, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and Associate Director for Cooperative Groups at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, joins i3 Health for a discussion that covers recent developments in genomic testing and targeted therapies, supportive care measures that can optimize quality of life, and strategies that members of the cancer care team can utilize to improve the outcomes of their patients with pancreatic cancer. Learning Objectives: Upon completion of this activity, participants should be able to: • Identify the role that biomarkers can play in predicting therapeutic efficacy and developing tailored approaches to treatment • Develop effective multidisciplinary approaches that can be used to enhance pancreatic cancer treatment and supportive care https://www.i3health.com/oda-pancreatic Faculty: Al B. Benson, MD, FACP, FASCO, Professor of Medicine, Northwestern University Feinberg School of Medicine

Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD is organized by i3 Health. Release: September 18, 2020 Expiration: September 17, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL. Learning Objectives: Upon completion of this activity, participants should be able to: • Assess efficacy and safety of novel BTK inhibitor therapy for MCL • Assess efficacy and safety of CAR T-cell therapy for MCL Faculty: Gilles Salles, MD, PhD Chief of the Lymphoma Service Memorial Sloan Kettering Cancer Center

Mayo Clinic Talks Podcast - Online is organized by Mayo Clinic. Course opens: 12/30/2019 Course expires: 12/29/2022 Available credit:  • 36.75 AMA PRA Category 1 Credit™ • 36.75 Attendance Overview: Mayo Clinic Talks is a weekly podcast show hosted by Darryl Chutka, M.D., a general internist at Mayo Clinic. Podcasting offers succinct, relevant, and accessible CME. The episodes in this course reflect commonly seen health problems in a primary care practice. Listen in as Dr. Chutka interviews experts on a variety of topics ranging from The Risks and Benefits of Coffee to Transgender Patient Care, back pain, management of sleep apnea, hormone therapy, and The Dangers of Distraction and Balancing Connectivity. Listen in the course or using your favorite podcast app, then return here to take a short assessment and claim credit. Learning Objectives: Upon completion of this course, learners should be able to: • Describe the current treatment recommendations for patients with hyperlipidemia. • List the various categories of hypertension. • Describe the current pharmacologic treatment available for patients with osteoporosis. • Participation in this Mayo Clinic online course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Treatment Advances in Gastrointestinal Stromal Tumor With Shreyaskumar Patel, MD is organized by i3 Health. Release: July 10, 2020 Expiration: July 9, 2021 Accreditation: Physicians i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.  Nursing Continuing Professional Development A maximum of 0.25 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.  Overview: The fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest therapeutic developments. Treatment for GIST has seen exciting progress this year, with two new FDA approvals for metastatic disease. This episode of Oncology Data Advisor features Dr. Shreyaskumar Patel, Robert R. Herring Distinguished Professor of Cancer Research and Center Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, in a discussion that covers the changing treatment landscape, adverse events of concern with novel therapies, and advice for members of the cancer care team as they seek to optimize outcomes for patients with GIST. Learning Objectives: Upon completion of this activity, participants should be able to: • Evaluate emerging data on later-line treatment selection for individual patients with GIST • Apply strategies to manage adverse events related to novel GIST treatments Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.

COVID-19 Infection and Surgical Patients Course is organized by Southern Medical Association (SMA). CME Release Date: April 18, 2020 Valid for credit through: April 18, 2021 Estimated time of completion: 1 hour Accreditation:  Southern Medical Association designates this Internet Activity (Enduring Material) for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Goals and Objectives: Dr. Iyoob Ilyas discusses the effect of the coronavirus on surgical patients. He will provide insight into why elective surgeries are being canceled or rescheduled, how emergency procedures are being addressed, and will offer recommendations for patients who develop surgical complaints.

Treating Conjunctivitis and Dry Eye Disease is organized by American Medical Association (AMA). Recorded Date: Feb 04, 2020 End Date: Feb 04, 2023 Duration: Clinical Review Audio 18 min 54 sec Accreditation: MOC/CME Information: 0.5 Credit CME Description: Conjunctivitis and dry eye disease are some of the most common conditions patients present with. They are usually benign entities that respond well to conservative measures and usually do not require medications. However, if medications are necessary, clinicians can find a comprehensive assessment of these drugs recently published in the December 2, 2019, issue of The Medical Letter. An excerpt from this article summarizing information about conjunctivitis and dry eye disease was published in the February 4, 2020 issue of JAMA. Kathryn Colby, MD, PhD, chair of the Department of Ophthalmology and Visual Science at the University of Chicago, explains in this podcast how to treat conjunctivitis and dry eye disease. Educational Objective: •  To understand how to treat conjunctivitis and dry eye disease.   Additional details will be posted as soon as information is available.

Ethics Talk: Ebola Responses in Colonial Context is organized by American Medical Association (AMA)  Recorded Date: Feb 06, 2020 End Date: Feb 06, 2023 Duration: Clinical Review Audio 24 min 21 sec Accreditation: MOC/CME Information: 0.5 Credit CME Description: Good epidemic responses require cross-disciplinary collaboration. Dr David Heymann talks about serving in an Ebola containment campaign and Dr Christy Rentmeester explains what clinicians should know about colonialism to promote health equity. Educational Objective:  • Identify key ethical values or principles at stake, as described in the program • Distinguish among factors of ethical, clinical, legal, social, and cultural significance • Articulate how central themes of clinical and ethical relevance in the program can influence health care practice • Explain at least one way in which micro-level clinical ethics questions intersect with broader macro-level policy questions in health care   Additional details will be posted as soon as information is available.

Ethics Talk: How Do We Prepare for Human Gene Editing? is organized by American Medical Association (AMA). Recorded Date: Feb 06, 2020 End Date: Feb 06, 2023 Duration: Clinical Review Audio 23 min 07 sec Accreditation: MOC/CME Information: 0.5 Credit CME Description: How should we prepare for rapid advancement of gene editing technology? This month on Ethics Talk, Dr Sean C. McConnell provides an introduction to gene editing and CRISPR technology and Scott J. Schweikart discusses what prudent governance requires. Educational Objective:  • Identify key ethical values or principles at stake, as described in the program • Distinguish among factors of ethical, clinical, legal, social, and cultural significance • Articulate how central themes of clinical and ethical relevance in the program can influence health care practice • Explain at least one way in which micro-level clinical ethics questions intersect with broader macro-level policy questions in health care Additional details will be posted as soon as information is available.